XERIS BIOPHARMA HOLDINGS, INC. Increase (Decrease) in Deferred Liabilities
XERIS BIOPHARMA HOLDINGS, INC. (XERS) reported Increase (Decrease) in Deferred Liabilities of -$238.00 thousand for the 9-month period ending 2022-09-30, per its 10-Q filed 2022-11-09.
Discontinued › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInDeferredLiabilities · last filed 2022-11-09
- XERIS BIOPHARMA HOLDINGS, INC. increase (decrease) in deferred liabilities for the quarter ending 2022-09-30 was -$154.00K.
- XERIS BIOPHARMA HOLDINGS, INC. increase (decrease) in deferred liabilities for the quarter ending 2022-06-30 was -$143.00K.
- XERIS BIOPHARMA HOLDINGS, INC. increase (decrease) in deferred liabilities for the quarter ending 2022-03-31 was $59.00K.
- XERIS BIOPHARMA HOLDINGS, INC. increase (decrease) in deferred liabilities for the quarter ending 2021-12-31 was $254.00K.
- XERIS BIOPHARMA HOLDINGS, INC. increase (decrease) in deferred liabilities for fiscal 2021 was $254.00K.
- XERIS BIOPHARMA HOLDINGS, INC. increase (decrease) in deferred liabilities for fiscal 2020 was -$447.00K.
| Period end | Increase (Decrease) in Deferred Liabilities 3 month | Increase (Decrease) in Deferred Liabilities 6 month | Increase (Decrease) in Deferred Liabilities 9 month | Increase (Decrease) in Deferred Liabilities 12 month |
|---|---|---|---|---|
| 2022-09-30 | -$154.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-09 | -$297.00K derived: sum of 2 quarters · filed 2022-11-09 | -$238.00K 10-Q · filed 2022-11-09 | $16.00K derived: sum of 4 quarters · filed 2022-11-09 |
| 2022-06-30 | -$143.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-10 | -$84.00K 10-Q · filed 2022-08-10 | $170.00K derived: sum of 3 quarters · filed 2022-08-10 | $170.00K derived: sum of 4 quarters · filed 2022-11-09 |
| 2022-03-31 | $59.00K 10-Q · filed 2022-05-11 | $313.00K derived: sum of 2 quarters · filed 2022-05-11 | $313.00K derived: sum of 3 quarters · filed 2022-11-09 | $313.00K derived: sum of 4 quarters · filed 2022-11-09 |
| 2021-12-31 | $254.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-11 | $254.00K derived: sum of 2 quarters · filed 2022-11-09 | $254.00K derived: sum of 3 quarters · filed 2022-11-09 | $254.00K 10-K · filed 2022-03-11 |
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-09 | $0.00 derived: sum of 2 quarters · filed 2022-11-09 | $0.00 10-Q · filed 2022-11-09 | |
| 2021-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-10 | $0.00 10-Q · filed 2022-08-10 | ||
| 2021-03-31 | $0.00 10-Q · filed 2022-05-11 | |||
| 2020-12-31 | -$447.00K 10-K · filed 2022-03-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| Xencor Inc (XNCR) | United States | $1.776B | -7.33 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Septerna, Inc. (SEPN) | United States | $1.783B | -63.01 |